PURPOSE: In another study, it was demonstrated that NADPH oxidase-derived reactive oxygen species (ROS) are important for ischemia-induced increases in vascular endothelial growth factor (VEGF) and retinal neovascularization. Diabetes-induced increases in retinal ROS, VEGF expression, and vascular permeability are accompanied by increases in the NADPH oxidase catalytic subunit NOX2 within the retinal vessels. The goal of this study was to evaluate the potential role of NOX2 and NADPH oxidase activity in the development of retinal vascular inflammation. METHODS: Studies were performed in wild-type mice, mice lacking NOX2, and mice treated with the NADPH oxidase inhibitor apocynin in models of endotoxemia and streptozotocin-induced diabetes. Intracellular adhesion molecule (ICAM)-1 expression was determined by Western blot analysis. Leukocyte adhesion was assessed by labeling adherent leukocytes with concanavalin A. Vascular permeability was assessed by extravasation of FITC-conjugated albumin. ROS production was determined by dichlorofluorescein imaging. RESULTS: Both endotoxemia- and diabetes-induced increases in ICAM-1 expression and leukostasis were significantly inhibited by deletion of NOX2, indicating that this enzyme is critically involved in both conditions. Moreover, apocynin treatment and deletion of NOX2 were equally effective in preventing diabetes-induced increases in ICAM-1, leukostasis, and breakdown of the blood-retinal barrier, suggesting that NOX2 is primarily responsible for these early signs of diabetic retinopathy. CONCLUSIONS: These data suggest that NOX2 activity has a primary role in retinal vascular inflammation during acute and chronic conditions associated with retinal vascular inflammatory reactions. Targeting this enzyme could be a novel therapeutic strategy for treatment of the retinopathies associated with vascular inflammation.
PURPOSE: In another study, it was demonstrated that NADPH oxidase-derived reactive oxygen species (ROS) are important for ischemia-induced increases in vascular endothelial growth factor (VEGF) and retinal neovascularization. Diabetes-induced increases in retinal ROS, VEGF expression, and vascular permeability are accompanied by increases in the NADPH oxidase catalytic subunit NOX2 within the retinal vessels. The goal of this study was to evaluate the potential role of NOX2 and NADPH oxidase activity in the development of retinal vascular inflammation. METHODS: Studies were performed in wild-type mice, mice lacking NOX2, and mice treated with the NADPH oxidase inhibitor apocynin in models of endotoxemia and streptozotocin-induced diabetes. Intracellular adhesion molecule (ICAM)-1 expression was determined by Western blot analysis. Leukocyte adhesion was assessed by labeling adherent leukocytes with concanavalin A. Vascular permeability was assessed by extravasation of FITC-conjugated albumin. ROS production was determined by dichlorofluorescein imaging. RESULTS: Both endotoxemia- and diabetes-induced increases in ICAM-1 expression and leukostasis were significantly inhibited by deletion of NOX2, indicating that this enzyme is critically involved in both conditions. Moreover, apocynin treatment and deletion of NOX2 were equally effective in preventing diabetes-induced increases in ICAM-1, leukostasis, and breakdown of the blood-retinal barrier, suggesting that NOX2 is primarily responsible for these early signs of diabetic retinopathy. CONCLUSIONS: These data suggest that NOX2 activity has a primary role in retinal vascular inflammation during acute and chronic conditions associated with retinal vascular inflammatory reactions. Targeting this enzyme could be a novel therapeutic strategy for treatment of the retinopathies associated with vascular inflammation.
Authors: Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman Journal: Diabetes Date: 2007-02 Impact factor: 9.461
Authors: LiFeng Zhang; Andrew Zalewski; Yuchuan Liu; Tomasz Mazurek; Scott Cowan; Jack L Martin; Susanna M Hofmann; Helen Vlassara; Yi Shi Journal: Circulation Date: 2003-07-14 Impact factor: 29.690
Authors: T Inoguchi; H Tsubouchi; T Etoh; M Kakimoto; T Sonta; H Utsumi; H Sumimoto; H Y Yu; N Sonoda; M Inuo; N Sato; N Sekiguchi; K Kobayashi; H Nawata Journal: Curr Med Chem Date: 2003-09 Impact factor: 4.530
Authors: Azza B El-Remessy; M Ali Behzadian; Gamal Abou-Mohamed; Telina Franklin; Robert W Caldwell; Ruth B Caldwell Journal: Am J Pathol Date: 2003-06 Impact factor: 4.307
Authors: Ping Chen; Austin M Guo; Paul A Edwards; Gary Trick; A Guillermo Scicli Journal: Am J Physiol Regul Integr Comp Physiol Date: 2007-07-25 Impact factor: 3.619
Authors: Yunpeng Du; Megan Cramer; Chieh Allen Lee; Jie Tang; Arivalagan Muthusamy; David A Antonetti; Hui Jin; Krzysztof Palczewski; Timothy S Kern Journal: FASEB J Date: 2015-02-09 Impact factor: 5.191
Authors: Ghulam Mohammad; Kaiser Alam; Mohammad Imtiaz Nawaz; Mohammad Mairaj Siddiquei; Ahmed Mousa; Ahmed M Abu El-Asrar Journal: J Physiol Biochem Date: 2015-06-04 Impact factor: 4.158
Authors: Wenbo Zhang; Modesto Rojas; Brenda Lilly; Nai-Tse Tsai; Tahira Lemtalsi; Gregory I Liou; Robert W Caldwell; Ruth B Caldwell Journal: Invest Ophthalmol Vis Sci Date: 2009-02-21 Impact factor: 4.799
Authors: Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell Journal: Invest Ophthalmol Vis Sci Date: 2009-10-15 Impact factor: 4.799